Last updated on August 2018

Strict IGF-1 Control in Acromegaly

Brief description of study

Acromegaly is a rare, chronic, and debilitating disease, usually caused by a benign tumor on the pituitary gland, which leads to excessive production of growth hormone (GH). GH excess in turn causes overproduction of another hormone called insulin-like growth factor-1 (IGF-1). IGF-1 levels are currently the most widely accepted measure of disease activity.

In Canada, medical therapy with a type of medicine called "somatostatin analogues" (SSA), such as octreotide and lanreotide, is recommended for treatment of acromegaly. However, studies have shown that a significant number of patients who take SSA medications alone remain with elevated levels of IGF-1 in their blood.

Another medication that is used to treat acromegaly is pegvisomant (PEGV), and the investigators plan to study whether strict control of IGF-1, by adding or optimizing the use of PEGV, results in a significant health benefits to patients who still have modestly high levels of IGF-1 in their blood.

Clinical Study Identifier: NCT02952885

Contact Investigators or Research Sites near you

Start Over

Stan Van Uum, MD

St. Joseph Health Care London
London, ON Canada
  Connect »

Marie-Claire Denis, MD

Centre hospitalier universitaire de Qu bec-Universit Laval
Quebec City, QC Canada
  Connect »

Heather Lochnan, MD

The Ottawa Hospital
Ottawa, ON Canada
  Connect »

Juan Andres Rivera Ramirez, MD

McGill University Health Centre
Montréal, QC Canada
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.